CA2294036C - Polyallylamine polymers for treating hypercholesterolemia - Google Patents
Polyallylamine polymers for treating hypercholesterolemia Download PDFInfo
- Publication number
- CA2294036C CA2294036C CA002294036A CA2294036A CA2294036C CA 2294036 C CA2294036 C CA 2294036C CA 002294036 A CA002294036 A CA 002294036A CA 2294036 A CA2294036 A CA 2294036A CA 2294036 C CA2294036 C CA 2294036C
- Authority
- CA
- Canada
- Prior art keywords
- crosslinking agent
- polymer
- crosslinked
- weight
- solid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 47
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims description 6
- 229920000083 poly(allylamine) Polymers 0.000 title description 19
- 150000001412 amines Chemical class 0.000 claims abstract description 18
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 239000003431 cross linking reagent Substances 0.000 claims description 27
- 239000000178 monomer Substances 0.000 claims description 22
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 11
- 239000003613 bile acid Substances 0.000 claims description 9
- 229920006037 cross link polymer Polymers 0.000 claims description 6
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 4
- 229920001519 homopolymer Polymers 0.000 claims description 4
- 230000009919 sequestration Effects 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 229920000080 bile acid sequestrant Polymers 0.000 claims description 3
- 125000005208 trialkylammonium group Chemical group 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 9
- 239000003833 bile salt Substances 0.000 abstract description 4
- 229940093761 bile salts Drugs 0.000 abstract description 3
- 239000007787 solid Substances 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 19
- -1 e.g. Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 238000003756 stirring Methods 0.000 description 14
- 238000008214 LDL Cholesterol Methods 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 10
- 235000012054 meals Nutrition 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 229940020428 renagel Drugs 0.000 description 5
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 description 5
- MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 201000005991 hyperphosphatemia Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- SJSZBOAQWPKFMU-UHFFFAOYSA-N n-(1-acetamidoethyl)acetamide Chemical compound CC(=O)NC(C)NC(C)=O SJSZBOAQWPKFMU-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- ABBZJHFBQXYTLU-UHFFFAOYSA-N but-3-enamide Chemical compound NC(=O)CC=C ABBZJHFBQXYTLU-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229920000768 polyamine Polymers 0.000 description 3
- HPILSDOMLLYBQF-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COC(CCC)OCC1CO1 HPILSDOMLLYBQF-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000004566 IR spectroscopy Methods 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229940096699 bile acid sequestrants Drugs 0.000 description 2
- RXKUYBRRTKRGME-UHFFFAOYSA-N butanimidamide Chemical compound CCCC(N)=N RXKUYBRRTKRGME-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229940069978 calcium supplement Drugs 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- YZSVECGEOCKDCQ-UHFFFAOYSA-N CN(C)C.CC=CC1=CC=CC=C1 Chemical compound CN(C)C.CC=CC1=CC=CC=C1 YZSVECGEOCKDCQ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010065973 Iron Overload Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011362 coarse particle Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940060367 inert ingredients Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- ZQXSMRAEXCEDJD-UHFFFAOYSA-N n-ethenylformamide Chemical compound C=CNC=O ZQXSMRAEXCEDJD-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002694 phosphate binding agent Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940056345 tums Drugs 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011240 wet gel Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87842297A | 1997-06-18 | 1997-06-18 | |
| US08/878,422 | 1997-06-18 | ||
| US92724797A | 1997-09-11 | 1997-09-11 | |
| US08/927,247 | 1997-09-11 | ||
| US08/979,096 US6423754B1 (en) | 1997-06-18 | 1997-11-26 | Method for treating hypercholesterolemia with polyallylamine polymers |
| US08/979,096 | 1997-11-26 | ||
| PCT/US1998/012422 WO1998057652A1 (en) | 1997-06-18 | 1998-06-15 | Polyallylamine polymers for treating hypercholesterolemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2294036A1 CA2294036A1 (en) | 1998-12-23 |
| CA2294036C true CA2294036C (en) | 2007-08-21 |
Family
ID=27420493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002294036A Expired - Lifetime CA2294036C (en) | 1997-06-18 | 1998-06-15 | Polyallylamine polymers for treating hypercholesterolemia |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6423754B1 (enExample) |
| EP (1) | EP0996454B1 (enExample) |
| JP (1) | JP4420143B2 (enExample) |
| KR (1) | KR100567751B1 (enExample) |
| CN (1) | CN1211091C (enExample) |
| AT (1) | ATE249228T1 (enExample) |
| AU (1) | AU735260C (enExample) |
| CA (1) | CA2294036C (enExample) |
| DE (1) | DE69818058T2 (enExample) |
| IL (1) | IL133434A (enExample) |
| MX (1) | MXPA99011826A (enExample) |
| MY (1) | MY125874A (enExample) |
| NZ (1) | NZ501719A (enExample) |
| TW (1) | TW526063B (enExample) |
| WO (1) | WO1998057652A1 (enExample) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW568788B (en) * | 1998-10-12 | 2004-01-01 | Chugai Pharmaceutical Co Ltd | Polymer combining with phosphoric acid and preparation containing the same |
| EP1293211A1 (en) * | 1998-12-23 | 2003-03-19 | G.D. Searle LLC. | Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications |
| PT1175451E (pt) * | 1999-04-16 | 2007-09-24 | Abbott Lab | ''processo para produção de cloridrato de polialilamina reticulada'' |
| US6362266B1 (en) | 1999-09-03 | 2002-03-26 | The Dow Chemical Company | Process for reducing cohesiveness of polyallylamine polymer gels during drying |
| US6180754B1 (en) | 1999-09-03 | 2001-01-30 | The Dow Chemical Company | Process for producing cross-linked polyallylamine polymer |
| US20020054903A1 (en) * | 1999-10-19 | 2002-05-09 | Joseph Tyler | Direct compression polymer tablet core |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| SK288217B6 (sk) | 2001-01-26 | 2014-08-05 | Merck Sharp & Dohme Corp. | Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie |
| BRPI0206641B8 (pt) | 2001-01-26 | 2021-05-25 | Merck Sharp & Dohme | uso de um inibidor da absorção de esteróis |
| EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
| ES2637020T3 (es) | 2001-04-18 | 2017-10-10 | Genzyme Corporation | Uso de polímero de amina para reducir la glucosa sérica |
| BR0209020A (pt) * | 2001-04-18 | 2004-08-10 | Genzyme Corp | Composição farmacêutica de polialilamina |
| WO2002085379A1 (en) * | 2001-04-18 | 2002-10-31 | Geltex Pharmaceuticals, Inc. | Method for improving vascular access in patients with vascular shunts |
| KR20040018359A (ko) * | 2001-04-18 | 2004-03-03 | 젠자임 코포레이션 | 지방족 폴리아민으로 ｘ 증후군을 치료하는 방법 |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| DE60216300T2 (de) | 2001-09-21 | 2007-06-28 | Schering Corp. | Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7273888B2 (en) * | 2001-11-16 | 2007-09-25 | Als Therapy Development Foundation, Inc. | Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis |
| AU2003282867A1 (en) * | 2002-10-22 | 2004-05-13 | Genzyme Corporation | Amine polymers for promoting bone formation |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| CA2517573C (en) | 2003-03-07 | 2011-12-06 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7459502B2 (en) * | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| US7385012B2 (en) * | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7767768B2 (en) * | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7335795B2 (en) * | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7449605B2 (en) * | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| CA2546601A1 (en) | 2003-11-19 | 2005-06-09 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| DE112005000725B4 (de) | 2004-03-30 | 2017-12-21 | Relypsa, Inc. (n.d.Ges.d. Staates Delaware) | Verfahren und Zusammensetzungen zur Behandlung von Ionen-Ungleichgewichten |
| US20050244367A1 (en) * | 2004-05-03 | 2005-11-03 | Ilypsa, Inc. | Phospholipase inhibitors localized in the gastrointestinal lumen |
| US20050276781A1 (en) * | 2004-06-09 | 2005-12-15 | Ross Edward A | Molecularly imprinted phosphate binders for therapeutic use |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| US20060177415A1 (en) * | 2004-11-01 | 2006-08-10 | Burke Steven K | Once a day formulation for phosphate binders |
| EP1869090A1 (en) * | 2005-03-16 | 2007-12-26 | Council Of Scientific And Industrial Research | An improved process for the preparation of crosslinked polyallylamine polymer. |
| RU2007148927A (ru) | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| JP2009507019A (ja) | 2005-09-02 | 2009-02-19 | ジェンザイム・コーポレーション | リン酸塩を除去する方法およびそれに使用される重合体 |
| AR056499A1 (es) * | 2005-09-06 | 2007-10-10 | Serapis Farmaceuticals Ltd | Compuestos |
| KR101547925B1 (ko) | 2005-09-15 | 2015-08-27 | 젠자임 코포레이션 | 아민 중합체에 대한 샤셋 제형 |
| JP2009536246A (ja) * | 2006-05-05 | 2009-10-08 | ゲンズイメ コーポレーション | ホスフェート捕捉剤としてのアミン縮合重合体 |
| CA2658338A1 (en) * | 2006-07-18 | 2008-01-24 | Genzyme Corporation | Amine dendrimers |
| WO2008042222A2 (en) | 2006-09-29 | 2008-04-10 | Genzyme Corporation | Amide dendrimer compositions |
| JP5535638B2 (ja) * | 2006-10-25 | 2014-07-02 | ウィスコンシン アルムニ リサーチ ファンデイション | リン酸塩吸収の低減方法 |
| US20100143385A1 (en) * | 2006-10-26 | 2010-06-10 | Mark Cook | Methods for reducing phosphate absorption |
| WO2008076242A1 (en) * | 2006-12-14 | 2008-06-26 | Genzyme Corporation | Amido-amine polymer compositions |
| SI2124884T1 (sl) | 2006-12-22 | 2019-09-30 | Ironwood Pharmaceuticals, Inc. | Pripravki, ki obsegajo sekvestrante žolčnih kislin, za zdravljenje motenj požiralnika |
| EP2114376A1 (en) * | 2007-02-23 | 2009-11-11 | Genzyme Corporation | Amine polymer compositions |
| WO2008109095A1 (en) * | 2007-03-08 | 2008-09-12 | Genzyme Corporation | Sulfone polymer compositions |
| US20100166696A1 (en) * | 2007-04-27 | 2010-07-01 | Dhal Pradeep K | Amido-amine dendrimer compositions |
| JP2011506449A (ja) * | 2007-12-14 | 2011-03-03 | ジェンザイム コーポレーション | コーティング医薬組成物 |
| PA8807201A1 (es) * | 2007-12-14 | 2009-07-23 | Genzyme Corp | Composiciones farmaceuticas |
| WO2009154747A1 (en) * | 2008-06-20 | 2009-12-23 | Genzyme Corporation | Pharmaceutical compositions |
| US8404784B2 (en) * | 2008-12-03 | 2013-03-26 | Navinta Llc | Manufacturing process of making polymeric amine salts |
| WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
| IT1394299B1 (it) * | 2009-05-12 | 2012-06-06 | Chimico Internaz Spa Lab | Procedimento per la preparazione di sevelamer |
| JP5285000B2 (ja) * | 2010-02-23 | 2013-09-11 | 富士フイルム株式会社 | 低密度リポ蛋白コレステロールの測定方法 |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9486433B2 (en) | 2012-10-12 | 2016-11-08 | Mochida Pharmaceuticals Co. Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| CN105592846A (zh) | 2013-03-15 | 2016-05-18 | 持田制药株式会社 | 用于治疗非酒精性脂肪性肝炎的组合物和方法 |
| US10441560B2 (en) | 2013-03-15 | 2019-10-15 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| JP6708764B1 (ja) * | 2019-01-28 | 2020-06-10 | 久保田 徹 | 機能水 |
| CN112047854B (zh) * | 2020-10-20 | 2021-07-02 | 中国科学院长春应用化学研究所 | 一种n-乙烯基烷基酰胺的制备方法 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB798488A (en) | 1956-01-09 | 1958-07-23 | Nat Aluminate Corp | Quaternary ammonium compounds and method for the preparation thereof |
| US2874132A (en) | 1956-11-02 | 1959-02-17 | Rohm & Haas | Anion-exchange resins for sugar decolorization and their preparation |
| BE580490A (fr) | 1958-07-15 | 1960-01-08 | Merck & Co Inc | Compositions et procédés pour abaisser la teneur en cholestérol du sang |
| US3383281A (en) | 1961-09-22 | 1968-05-14 | Merck & Co Inc | Method for binding bile acids in vivo |
| US3308020A (en) | 1961-09-22 | 1967-03-07 | Merck & Co Inc | Compositions and method for binding bile acids in vivo including hypocholesteremics |
| US3288770A (en) | 1962-12-14 | 1966-11-29 | Peninsular Chem Res Inc | Water soluble quaternary ammonium polymers |
| CH486202A (de) | 1966-05-31 | 1970-02-28 | Agripat Sa | Mikrobizides Mittel |
| US3562266A (en) | 1969-05-26 | 1971-02-09 | Montedison Spa | Quaternary ammonium halides having a 2-chloro cyclohexyl or 2-chloro alkyl substituent |
| BE756035A (fr) | 1969-09-12 | 1971-03-11 | Inveresk Res Int | Polymeres pontes |
| US3803237A (en) | 1969-11-03 | 1974-04-09 | Upjohn Co | Reaction products of polyethylenepolyamines and chlorohydrins or epoxy containing compounds |
| NL7017227A (enExample) | 1969-12-27 | 1971-06-29 | ||
| US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
| US3980770A (en) | 1971-06-04 | 1976-09-14 | Pharmacia Aktiebolag | Polymerization products containing amino groups useful in serum cholesterol level control |
| US4217429A (en) | 1973-06-11 | 1980-08-12 | Merck & Co., Inc. | Poly-[(methylimino)trimethylene] |
| US4205064A (en) | 1973-06-11 | 1980-05-27 | Merck & Co., Inc. | Bile acid sequestering composition containing poly[{alkyl-(3-ammoniopropyl)imino}-trimethylenedihalides] |
| US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
| CS187563B1 (en) | 1974-02-08 | 1979-02-28 | Petr Strop | Method of preparation of the hydrophilic homogeneous or macroporous annexes |
| CS173201B1 (enExample) | 1974-02-13 | 1977-02-28 | ||
| US4016209A (en) | 1975-04-23 | 1977-04-05 | Merck & Co., Inc. | 3-[N'-(3-Halopropyl)-N-'-methylamino]-N,N,N-trimethyl-1-propanaminium halide and acid addition salts thereof |
| US4071478A (en) | 1976-06-07 | 1978-01-31 | Merck & Co., Inc. | Controlled partially cross-linked 3,3-ionenes |
| FI67483C (fi) | 1977-02-17 | 1985-04-10 | Merck & Co Inc | Foerfarande foer framstaellning av ett icke adhesivt friflytande farmakologiskt godtagbart gallsyrakomplexbildande adsorbatpreparat |
| IT1106718B (it) | 1978-12-21 | 1985-11-18 | Alfa Farmaceutici Spa | Composizioni a base di resine anioniche salificate farmacologicamente attive |
| US4426489A (en) | 1980-02-21 | 1984-01-17 | The Dow Chemical Company | Surface active polymeric surfactants containing side chain hydrophobes |
| GB2090605B (en) | 1980-12-12 | 1984-09-05 | Smith & Nephew Ass | Polymer of diallyl ammonium monomers pharmaceutical compositions thereof |
| JPS5879022A (ja) | 1981-11-04 | 1983-05-12 | Bitamin Kenkyusho:Kk | 第四級窒素原子を含有する新規な金属架橋高分子化合物、その製法及び該高分子化合物を有効成分とする高脂血症治療剤 |
| WO1983002392A1 (fr) | 1982-01-18 | 1983-07-21 | Kihara, Kunio | Medicament abaissant le taux de cholesterol |
| JPS6090243A (ja) | 1983-10-25 | 1985-05-21 | Nitto Boseki Co Ltd | 小球状モノアリルアミン橋かけ重合体の製造方法 |
| US4528347A (en) | 1983-11-10 | 1985-07-09 | 501 Nitto Boseki, Co. Ltd | Process for producing polymers of monoallylamine |
| JPS60106803A (ja) | 1983-11-14 | 1985-06-12 | Nitto Boseki Co Ltd | アリル尿素重合体の製造方法 |
| AU551886B2 (en) | 1983-11-14 | 1986-05-15 | Nitto Boseki Co. Ltd. | Poly(allylamine) derivatives |
| CA1220897A (en) | 1984-01-11 | 1987-04-21 | Kiyoshi Shimizu | Process for producing polymers of monoallylamine |
| DE3572985D1 (en) | 1984-05-11 | 1989-10-19 | Bristol Myers Co | Novel bile sequestrant resin and uses |
| US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
| DE3800199A1 (de) | 1988-01-07 | 1989-07-20 | Sandoz Ag | Seitenkettenhaltige vinylpolymere |
| GB8829088D0 (en) | 1988-12-13 | 1989-01-25 | Smith Kline French Lab | Compounds |
| US5236701A (en) | 1989-07-19 | 1993-08-17 | Lowchol Scientific Inc. | Ingestible hydrophilic polymeric amines useful for lowering blood cholesterol |
| GB8928278D0 (en) | 1989-12-14 | 1990-02-21 | Smith Kline French Lab | Compounds |
| CA2040996A1 (en) | 1990-05-02 | 1991-11-03 | Robert L. Albright | Composition and method for controlling cholesterol |
| GB9011332D0 (en) | 1990-05-21 | 1990-07-11 | Smith Kline French Lab | Compounds |
| IE914179A1 (en) | 1990-12-07 | 1992-06-17 | Ici Plc | Nitrogen derivatives |
| US5055197A (en) | 1991-04-05 | 1991-10-08 | Rohm And Haas Company | Process for removing residual monomers and oligemers from amine-containing polymers |
| JP3247435B2 (ja) | 1992-07-11 | 2002-01-15 | 日産アルティア株式会社 | 芯材添設型樹脂製車両用ルーフレールの製造方法及び車両用ルーフレール |
| DK0580079T3 (da) | 1992-07-22 | 1997-06-30 | Hoechst Ag | Tværbundne, nitrogenholdige vinylcopolymerer, fremgangsmåde til deres fremstilling samt anvendelse af disse forbindelser |
| DE59307535D1 (de) | 1992-07-22 | 1997-11-20 | Hoechst Ag | Hydrophile Zentren aufweisende Polyvinylamin-Derivate, Verfahren zu ihrer Herstellung sowie die Verwendung der Verbindungen als Arzneimittel, Wirkstoffträger und Nahrungsmittelhilfsstoff |
| HUT72658A (en) | 1992-08-20 | 1996-05-28 | Du Pont | Crosslinked polymeric ammonium salts and pharmaceutical compositions containing them |
| US5451397A (en) | 1992-12-21 | 1995-09-19 | Rohm And Haas Company | Bile acid sequestrant |
| JPH06321786A (ja) * | 1993-05-12 | 1994-11-22 | Sekisui Chem Co Ltd | 胆汁酸腸管吸収抑制剤 |
| US5487888A (en) | 1993-05-20 | 1996-01-30 | Geltex, Inc. | Iron-binding polymers for oral administration |
| US5618530A (en) | 1994-06-10 | 1997-04-08 | Geltex Pharmaceuticals, Inc. | Hydrophobic amine polymer sequestrant and method of cholesterol depletion |
| US5624963A (en) | 1993-06-02 | 1997-04-29 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5607669A (en) * | 1994-06-10 | 1997-03-04 | Geltex Pharmaceuticals, Inc. | Amine polymer sequestrant and method of cholesterol depletion |
| JPH09500368A (ja) | 1993-06-02 | 1997-01-14 | ジェルテックス ファーマシューティカルズ，インコーポレイテッド | 胆汁酸塩を除去するための組成物および方法 |
| US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5414068A (en) | 1994-01-24 | 1995-05-09 | Rohm And Haas Company | Crosslinked anion exchange particles and method for producing the particles |
| TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| US5792749A (en) * | 1997-01-09 | 1998-08-11 | Virginia Commonwealth University | Method and composition for lowering low density lipoprotein cholesterol |
-
1997
- 1997-11-26 US US08/979,096 patent/US6423754B1/en not_active Expired - Lifetime
-
1998
- 1998-06-15 DE DE69818058T patent/DE69818058T2/de not_active Expired - Lifetime
- 1998-06-15 CN CNB988071118A patent/CN1211091C/zh not_active Expired - Lifetime
- 1998-06-15 KR KR1019997011968A patent/KR100567751B1/ko not_active Expired - Lifetime
- 1998-06-15 JP JP50464599A patent/JP4420143B2/ja not_active Expired - Lifetime
- 1998-06-15 EP EP98930234A patent/EP0996454B1/en not_active Expired - Lifetime
- 1998-06-15 IL IL13343498A patent/IL133434A/xx not_active IP Right Cessation
- 1998-06-15 WO PCT/US1998/012422 patent/WO1998057652A1/en not_active Ceased
- 1998-06-15 AU AU79675/98A patent/AU735260C/en not_active Expired
- 1998-06-15 NZ NZ501719A patent/NZ501719A/en not_active IP Right Cessation
- 1998-06-15 MX MXPA99011826A patent/MXPA99011826A/es active IP Right Grant
- 1998-06-15 CA CA002294036A patent/CA2294036C/en not_active Expired - Lifetime
- 1998-06-15 AT AT98930234T patent/ATE249228T1/de not_active IP Right Cessation
- 1998-06-17 MY MYPI98002704A patent/MY125874A/en unknown
- 1998-07-09 TW TW087109749A patent/TW526063B/zh not_active IP Right Cessation
-
2002
- 2002-05-29 US US10/158,207 patent/US20030086898A1/en not_active Abandoned
-
2006
- 2006-02-01 US US11/344,862 patent/US20060239959A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1029920A1 (en) | 2001-04-20 |
| US20030086898A1 (en) | 2003-05-08 |
| KR20010013943A (ko) | 2001-02-26 |
| JP2002516613A (ja) | 2002-06-04 |
| US20060239959A1 (en) | 2006-10-26 |
| WO1998057652A1 (en) | 1998-12-23 |
| CN1211091C (zh) | 2005-07-20 |
| CA2294036A1 (en) | 1998-12-23 |
| DE69818058T2 (de) | 2004-07-08 |
| NZ501719A (en) | 2001-10-26 |
| AU735260B2 (en) | 2001-07-05 |
| TW526063B (en) | 2003-04-01 |
| MXPA99011826A (es) | 2002-07-02 |
| DE69818058D1 (de) | 2003-10-16 |
| IL133434A0 (en) | 2001-04-30 |
| EP0996454B1 (en) | 2003-09-10 |
| IL133434A (en) | 2005-09-25 |
| JP4420143B2 (ja) | 2010-02-24 |
| AU735260C (en) | 2002-03-28 |
| KR100567751B1 (ko) | 2006-04-05 |
| ATE249228T1 (de) | 2003-09-15 |
| AU7967598A (en) | 1999-01-04 |
| MY125874A (en) | 2006-08-30 |
| EP0996454A1 (en) | 2000-05-03 |
| US6423754B1 (en) | 2002-07-23 |
| CN1263468A (zh) | 2000-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2294036C (en) | Polyallylamine polymers for treating hypercholesterolemia | |
| EP1416942B1 (en) | Amine polymers for treating gout and binding uric acid | |
| AU746876B2 (en) | Method for treating hypercholesterolemia with unsubstituted polydiallylamine | |
| CA2349620C (en) | Use of aliphatic polyamines for reducing oxalate | |
| AU2002257145B2 (en) | Method for lowering serum glucose | |
| US20020187120A1 (en) | Method for treating gout and reducing serum uric acid | |
| AU2002257145A1 (en) | Method for lowering serum glucose | |
| ZA200308063B (en) | Method of lowering serum glucose. | |
| US20020182168A1 (en) | Method for reducing copper levels and treating copper toxicosis | |
| WO2002085379A1 (en) | Method for improving vascular access in patients with vascular shunts | |
| EP1923064B1 (en) | Use of amine polymer for lowering serum glucose | |
| HK1029920B (en) | Polyallylamine polymers for treating hypercholesterolemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180615 |